News coverage about AtriCure (NASDAQ:ATRC) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. AtriCure earned a news impact score of 0.02 on Accern’s scale. Accern also gave press coverage about the medical device company an impact score of 46.894104730508 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

AtriCure (NASDAQ:ATRC) opened at $17.11 on Friday. AtriCure has a 1-year low of $15.77 and a 1-year high of $25.18. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.28 and a quick ratio of 1.65. The firm has a market capitalization of $590.54, a PE ratio of -16.77 and a beta of 0.66.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Wednesday, November 1st. The medical device company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.02. The company had revenue of $42.20 million for the quarter, compared to the consensus estimate of $43.44 million. AtriCure had a negative return on equity of 20.28% and a negative net margin of 19.40%. AtriCure’s revenue was up 10.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.21) earnings per share. equities research analysts forecast that AtriCure will post -0.96 EPS for the current year.

A number of research analysts have recently issued reports on the company. Zacks Investment Research raised AtriCure from a “sell” rating to a “hold” rating in a report on Monday, October 2nd. Canaccord Genuity reaffirmed a “buy” rating and set a $28.00 price target on shares of AtriCure in a report on Monday, October 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target (down from $25.00) on shares of AtriCure in a report on Tuesday, January 16th. TheStreet downgraded AtriCure from a “c-” rating to a “d+” rating in a report on Wednesday, November 29th. Finally, ValuEngine downgraded AtriCure from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. AtriCure currently has an average rating of “Hold” and a consensus target price of $24.33.

In other AtriCure news, CFO M. Andrew Wade sold 2,000 shares of the company’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $18.41, for a total value of $36,820.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director B Kristine Johnson purchased 1,500 shares of AtriCure stock in a transaction on Wednesday, November 8th. The stock was bought at an average price of $18.36 per share, with a total value of $27,540.00. Following the transaction, the director now owns 10,969 shares of the company’s stock, valued at $201,390.84. The disclosure for this purchase can be found here. Corporate insiders own 10.00% of the company’s stock.

WARNING: “AtriCure (ATRC) Given Daily News Impact Score of 0.02” was published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at

AtriCure Company Profile

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Insider Buying and Selling by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with's FREE daily email newsletter.